The biotech’s experimental medicine meaningfully improved multiple signs and symptoms of patients with NASH, a common liver disease that's proven a tough target for several drugmakers. 

The startup is the first young drugmaker in more than four months to seek an IPO of at least $100 million, a once common occurrence that's become rare following this year's sector-wide correction.

The money will help fund development of a TYK2 inhibitor that Nimbus CEO Jeb Keiper claims is more selective than Bristol Myers’ Sotyktu.

Jason Cole, who replaced former CFO Gina Consylman in March, is leaving six months later to “pursue new career opportunities,” the company said.

The investment is meant to improve Novartis’ capacity for developing and manufacturing biologic medicines that make up a larger share of its pipeline. 

Results from the company’s Phase 3 study show Lumakras outperformed chemotherapy. But that effect didn’t translate into patients living longer.

Scientists at Pretzel believe fixing mutated mitochondrial DNA with a mix of small molecule therapies and gene editing could be key to solving a number of hard-to-treat diseases.

You need current, reliable data, but other factors are critical in assessing this information.

Sotyktu has been on the pharma’s top pipeline candidates and its clearance continues a string of positive regulatory news for the company.

Comments by Billy Dunn, head of the FDA’s neuroscience office, played a major role in a vote by an advisory panel Wednesday in support of the medicine, which is in the final stages of regulatory review. 

The high end of the company’s estimates assumes a $100 price per dose and that half of all U.S. adults will receive a yearly booster.

David Kaslow, the lead scientist at a global public health nonprofit, will succeed Marion Gruber, who retired last fall amid her dissent on the timing of COVID-19 vaccine boosters.